Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Immuno-mechanics

Financiado

Cerrado

ENGINEERING CELLULAR SELF‐ORGANISATION BY CONTROLLING THE IMMUNO-MECHANICAL INT...

ENGINEERING CELLULAR SELF‐ORGANISATION BY CONTROLLING THE IMMUNO-MECHANICAL INTERPLAY Both scar formation and restitutio ad integrum during bone regeneration rely on cellular self-organisation that involve cell contraction and fibronectin/collagen formation. This early stage of cellular self-organization is later f... ver más

31/12/2027

CHARITE UNIVERSIT...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-08-18

ERC-2021-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CHARITE UNIVERSITAETSMEDIZI...

2.49M€ | Lider

Proyectos interesantes

PID2020-116141GB-I00

Medical Technol...

Applied Physics

145K€ Cerrado

PID2020-112566GB-I00

Medical Technol...

Biotechnology

321K€ Cerrado

BONEMECHBIO

Medical Technol...

Applied Physics

1M€ Cerrado

PhysCoMeT

Medical Technol...

Applied Physics

1M€ Cerrado

PID2020-112981RB-I00

Medical Technol...

Applied Physics

440K€ Cerrado

CoEvolve

Medical Technol...

Biophysics

1M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 64 meses Fecha Inicio: 2022-08-18
Fecha Fin: 2027-12-31

Líder del proyecto

CHARITE UNIVERSITAETSMEDIZIN BERLIN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Both scar formation and restitutio ad integrum during bone regeneration rely on cellular self-organisation that involve cell contraction and fibronectin/collagen formation. This early stage of cellular self-organization is later followed by angiogenesis and mineralisation. Scar-free regeneration of physiological tissue homeostasis requires balanced downregulation of early inflammation, however little is understood of the immune-mechanical coupling involved. We aim to lay the foundation for reducing patient suffering resulting from scarring by combining two distinct scientific worlds, for which we have been a major driving force: the distinct regulation of local inflammation and the mechano-biology during regeneration. By combining both of our areas of expertise, we aim to harvest the potential of the novel cross-disciplinary field Immuno-Mechanics. This ambitious project concentrates first on identifing the different mechanical niches that immune cells experience early in successful healing and non-healing. Second, we will engineer synthetic niches to control fibroblasts and fibroblast-immune cell interactions to steer cell self-organisation and matrix formation in vitro. Third, we plan to verify that these synthetic niches reprogram hematoma composition and can thus reduce later scarring in vivo. The proposed experiments are challenging as they have never been done this way before, but are feasible since they capitalise on our strengths in osteo-immunology and mechano-biology. Novel technologies will be combined in a unique way to engineer the immune-mechanical cell niche, to passivate activated immune cells and to reprogramme cell fate. This will allow us to substantially advance the basic understanding of the interplay between immune cells and their mechanical niche during early regeneration. By harnessing the mechanisms of the immune-mechanics interplay, we will lay the foundation for advancing immune-modulatory therapies to reduce harmful scarring.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores